Physician profile
Judith Giunta
NPI 1386940385
$1,656.43
in general payments reported to CMS, 2019-2025
12 companies · $49.99 in 2025
The $49.99 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $332 · 2022: $246 · 2024: $20.31 · 2025: $49.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $408.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $281.56 | 2019-2020 | |
| Novo Nordisk INC | $251.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $243.64 | 2019 | |
| Medtronic Minimed, INC. | $120.00 | 2019 | |
| Valeritas, INC. | $93.07 | 2019 | |
| Dexcom, INC. | $77.02 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.25 | 2022 | |
| Medtronic, INC. | $59.54 | 2022 | |
| Tandem Diabetes Care, INC. | $20.61 | 2019 | |
| Chiesi USA, INC. | $20.31 | 2024 | Myalept |
| Insulet Corporation | $18.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Giunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.